No Data
No Data
Property data banks, Lifenet Life Insurance, etc.
<4389>Property Data Bank Co., Ltd. Hikari Communication Co., Ltd. Stock Ownership Ratio -% → 5.06% Reporting Obligation Date 2024/05/16 <4564>OncoTherapy Science Co., Ltd. Long Corridor Asset Management Limited (Long Corridor Asset Management Limited) Stock Ownership Ratio 17.67% → 16.20% Reporting Obligation Date 2024/0
Digital Plus, Genext, etc.
<3133>Kaiho Co., Ltd. Yamada Toru Stock Ownership Ratio 12.99% → 14.18% Reporting Obligation Date 2024/04/26 <3237>Intrans Co., Ltd. Intrans LLC Inbound Investment Stock Ownership Ratio 43.50% → 31.27% Reporting Obligation Date 2024/05/08 <3491>GA Technology Co., Ltd. Ryu Higuchi Stock Holding Ratio 43.17% → 42.35% Report
FunPep - 1Q concludes an option agreement with Shionogi Pharmaceutical regarding the antibody-inducing peptide “FPP004X”
FunPep <4881> announced consolidated financial results for the 1st quarter (January to March 24) of the fiscal year ending 2024/12 on the 13th. Sales increased 54.8% from the same period last year to 50 billion yen, operating loss was 183 million yen (loss of 378 million yen in the same period last year), ordinary loss was 170 million yen (loss of 343 million yen), and quarterly net loss attributable to parent company shareholders was 168 million yen (341 million yen). About the antibody-inducing peptide project, the antibody-inducing peptide “FPP003” (label
FunPep 1Q Loss Y168.00M Vs Loss Y341.00M
FunPep Co. Ltd. (4881.TO) Japan 1st Quarter Ended March 31 GROUP 2024 2023 Revenue Y0.00 mln Y0.00 mln Operating Profit (Y183.00 mln
FUNPEP: Quarterly Report - 12th Quarter (2024/01/01 - 2024/03/31)
FUNPEP: Summary of Financial Results for the 1st Quarter Ending 2024/12 [Japanese GAAP] (Consolidated)
No Data